New Options For Japan As More COVID-19 Vaccines Finally Approved
Nods For Moderna, AstraZeneca
Japan has granted emergency approvals to two more vaccines for COVID-19, both from multinational developers, as it finally expands a so far very limited armory against the pandemic.
You may also be interested in...
India has waived the need for local clinical trials for COVID-19 vaccines already approved in certain other countries, while the WHO has added a Chinese vaccine to its emergency use list. Meanwhile, South Korea issues new guidance for local vaccine trials and Japan gives more money to COVAX.
Moderna's mRNA-1273 vaccine prevented significant illness after two doses in all patients in the TeenCOVE trial, ages 12-18. The company will submit the data to global regulators in June. Meanwhile, J&J has applied for the Japanese approval of its vaccine, Moderna progresses plans in Korea, and India plans to ramp up vaccine supplies.
GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium.